Sequenom Corp fka SQNM

[surf1944]

7:36AM Sequenom: Xenomics' preliminary investigation leads the company to believe Sequenom willfully manipulated its down syndrome data in its presentations (SQNM) 4.18 : Xenomics (XNOM.PK) announced that an ongoing internal investigation by Xenomics' personnel of the events surrounding its licensing deal with SQNM in late Oct, 2008 leads it to conclude that Sequenom purposely misled the co- fraudulently inducing Xenomics into granting Sequenom an exclusive license to its transrenal technology. SQNM announced success in developing a Down Syndrome test in late 2008 was the principal factor in Xenomics' decision to exclusively license its core Transrenal DNA and RNA technology in the area of fetal diagnostics to Sequenom. Xenomics is presently suing Sequenom to recover the Transrenal DNA and RNA technology as well as for specific and general damages.